Liraglutide: A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety/Tolerability, Pharmacokinetics & Pharmacodynamics of Liraglutide in Pediatric (10-17 Years Old) With Type 2 Diabetes

Trial Profile

Liraglutide: A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety/Tolerability, Pharmacokinetics & Pharmacodynamics of Liraglutide in Pediatric (10-17 Years Old) With Type 2 Diabetes

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 05 Oct 2012 Results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
    • 12 Jun 2012 Results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
    • 03 Oct 2011 Actual end date (September 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top